Published online Oct 14, 2023. doi: 10.3748/wjg.v29.i38.5395
Peer-review started: June 6, 2023
First decision: August 8, 2023
Revised: August 21, 2023
Accepted: September 26, 2023
Article in press: September 26, 2023
Published online: October 14, 2023
Processing time: 128 Days and 4.4 Hours
The screening practices for hepatitis D virus (HDV) are diverse and non-standardized worldwide, and the exact prevalence of HDV is uncertain.
To estimate the prevalence of HDV in Jilin Province, China.
Promoting research on the prevalence of HDV can help raise awareness of chronic hepatitis D, improve screening rate and identify hepatitis D patients as early as possible to reduce HDV transmission.
We collected 5594 serum samples from patients with hepatitis B in Jilin Province, China (3293 males and 2301 females, age range of 2 to 89 years) and then conducted tests for hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV) DNA, anti-hepatitis D antigen (HDAg), and HDV RNA.
The prevalence of anti-HDAg and HDV RNA among hepatitis B patient were 3.6% (3.2%-4.2%) and 1.2% (0.9%-1.5%), respectively, 87.69% of hepatitis D patients were 51-70 years old. HDV infection screening positive rate of patients with HBV DNA levels below 2000 IU/mL (2.0%) was higher than those above 2000 IU/mL (0.2%). Among anti-HDAg positive patients, the HDV RNA positive rate was positively correlated with the HBsAg level and anti-HDAg level. There was a weak correlation between HBsAg and anti-HDAg levels among hepatitis D patients.
Our study highlights the importance of considering multiple factors when assessing the severity of HDV infection, comprehensive evaluation of patients’ clinical and laboratory parameters is necessary for proper diagnosis and treatment.
From the perspective of medical institutions.